Heron Therapeutics, Inc. (HRTX)
| Market Cap | 337.64M |
| Revenue (ttm) | 98.30M |
| Net Income (ttm) | -216.80M |
| Shares Out | 118.89M |
| EPS (ttm) | -2.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,741,097 |
| Open | 2.83 |
| Previous Close | 2.90 |
| Day's Range | 2.80 - 3.07 |
| 52-Week Range | 2.19 - 9.45 |
| Beta | 0.83 |
| Analysts | Buy |
| Price Target | 10.63 (+274.3%) |
| Earnings Date | Feb 27, 2023 |
About HRTX
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycli... [Read more]
Financial Performance
In 2021, HRTX's revenue was $86.35 million, a decrease of -2.59% compared to the previous year's $88.64 million. Losses were -$220.68 million, -2.90% less than in 2020.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for HRTX stock is "Buy." The 12-month stock price forecast is $10.63, which is an increase of 274.30% from the latest price.
News
Heron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises
- Preliminary Annual Net Product Sales Across the Company Grew 24% to $106.7 Million in 2022, Compared to Annual Net Product Sales in 2021 - - Preliminary Fourth-Quarter 2022 Net Product Sales for ZYN...
Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF® and Provision in Newly Passed Congressional Bill Anticipated to Provide Separate Reimbursement Outside of the Packaged Surgical Payment for ZYNRELEF
- Supplemental New Drug Application Submitted Requesting Expansion of Indication to Broadly Cover Soft Tissue and Orthopedic Surgical Procedures - - Omnibus Spending Bill (H.R. 2617) Includes Provisio...
Heron Therapeutics Announces Virtual Presentation at Evercore ISI 5th Annual HealthCONx Conference
SAN DIEGO , Nov. 21, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treat...
Heron Therapeutics (HRTX) Reports Q3 Loss, Tops Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 2.56% and 1.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Highlights Recent Corporate Updates
- APONVIE™ approval by FDA, U.S. launch planned for Q1 2023 – - ZYNRELEF ® unit demand grew 18% over prior quarter in Q3 2022 – - Oncology Care Franchise net product sales grew 13% over prior year in...
Hurry! 7 Pitiful Stocks to Sell Before 2022 Ends
When it comes to certain stocks to sell, being overly optimistic can become a liability. No, this is not a popular topic by any means, usually arousing anger among the investing faithful.
Heron Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
SAN DIEGO , Nov. 1, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatm...
4 No-Brainer Penny Stocks to Buy if You Have Money to Invest
Penny stocks have always fascinated investors. That's because higher-risk, lower-priced penny stocks to buy can be portfolio game-changers.
7 Unknown Biotech Stocks That Could Rocket in 2023
Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.
Heron Therapeutics Announces U.S. FDA Approval of APONVIE™ (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV)
- APONVIE is the first and only intravenous (IV) formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicatedfor PONV - - Delivered via a single 30-second IV injection, APONVIE has de...
All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Buy
Heron Therapeutics (HRTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
How Much Upside is Left in Heron Therapeutics (HRTX)? Wall Street Analysts Think 91%
The average of price targets set by Wall Street analysts indicates a potential upside of 90.6% in Heron Therapeutics (HRTX). While the effectiveness of this highly sought-after metric is questionable,...
Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -10% and 11.98%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics Announces $76.5 Million Private Placement Financing
SAN DIEGO , Aug. 9, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing ...
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Highlights Recent Corporate Updates
- ZYNRELEF® launch trend continues at a strong pace with sequential quarterly product sales increase of 140% and unit demand increase of 47% - - Oncology Care Franchise net product sales grew 12% over...
Heron Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
SAN DIEGO , Aug. 2, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing ...
7 Biotech Stocks to Buy for Q3
These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. The post 7 Biotech Stocks to Buy for Q3 appeared first on I...
Heron Therapeutics to cut about one-third of its workforce as part of cost-cutting plan
Heron Therapeutics Inc. HRTX, +3.26% said Thursday it will lay off about one-third of its workforce as part of a restructuring expected to save $43 million a year. The biotechnology company's stock wa...
Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability
- Changes result in annualized cost savings of $43M, extending the cash runway; Company is continuing to reduce external spend - - Reduces organization headcount by 34% - - Priorities remain on comme...
Heron Therapeutics Announces Publication Showing ZYNRELEF® as the Foundation of a Perioperative Non-Opioid Multimodal Analgesic Regimen Reduced Severe Pain and Opioid Use in Patients Undergoing Total Knee Arthroplasty
SAN DIEGO , June 14, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing...
Heron Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference
SAN DIEGO , May 26, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing ...
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Heron Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK , May 26, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...